Blood test may predict dangerous MS rebound after stopping popular drug

NCT ID NCT05828901

Terminated Knowledge-focused Sponsor: Insel Gruppe AG, University Hospital Bern Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small, early-terminated study explored whether measuring certain receptors on immune cells could predict disease activity and rebound risk in multiple sclerosis patients taking or stopping ozanimod. Researchers analyzed blood samples from 23 adults with relapsing-remitting MS before and after starting or stopping the drug. The goal was to find a biomarker that could guide safer treatment decisions, but the study's limited size and early stop mean the findings are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ozanimod
What this could lead to: If successful, this could help doctors identify which MS patients are at risk of severe relapse after stopping ozanimod, allowing safer treatment switches.
What could go wrong: The study was terminated early with only 23 participants, so results are limited. It was exploratory, not designed to prove a treatment works, and the biomarker approach may not be reliable in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Neurology department

Bern, 3010, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.